Clinical trials: Ototoxicity, Radiation-Induced
Head and Neck Cancer Survivors, Cancer of the Head and Neck Surviors
Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)
To evaluate the effectiveness, feasibility, acceptability, and appropriateness of an ototoxicity screening protocol among head and neck (H\&N) cancer patients followed in survivorship clinic that received cisplatin-based…
- Trial name
- NCT05789316
- Testing
- Ototoxicity Screening Protocol
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Washington University School of Medicine
Ototoxic Hearing Loss, Ototoxic Hearing Loss, Bilateral
Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity
The purpose of this study is to assess the efficacity of N-acetylcystein against Cisplatin-induced ototoxicity.
- Conditions
- Ototoxic Hearing Loss, Ototoxic Hearing Loss, Bilateral, Ototoxicity, Tinnitus
- Trial name
- NCT04226456
- Testing
- N-acetyl cysteine
- Where
- Belgium
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Cisplatin Adverse Reaction, Cisplatin Nephrotoxicity
Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients
Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients
- Conditions
- Cisplatin Adverse Reaction, Cisplatin Nephrotoxicity, Cisplatin Induced Peripheral Neuropathy, Cancer Patients
- Trial name
- NCT06297369
- Testing
- N acetyl cysteine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Cisplatin Adverse Reaction
Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity
Cisplatin is an effective anti-cancer drug for the treatment of many solid tumors in humans. Although the clinical response to cisplatin chemotherapy is encouraging, the nephrotoxicity and ototoxicity of the drug makes it…
- Trial name
- NCT04817904
- Testing
- Rosuvastatin 10mg
- Where
- Egypt
- Volunteers
- 65 people
- Sponsor
- Cairo University
Cisplatin Ototoxicity
Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment
Cisplatin is a widely used chemotherapeutic agent for the treatment of various malignant neoplasms, including testicular, ovarian, bladder, cervix uteri, head and neck and lung cancers.
- Trial name
- NCT01372904
- Testing
- Dexamethasone Phosphate
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Meir Medical Center
Solid Tumors, Ototoxicity
Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy
Platinum based chemotherapy (mainly Cisplatin) is known to cause a variety of adverse effects, including Ototoxicity and nephrotoxicity.
- Trial name
- NCT06553157
- Testing
- Statin
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Minia University
Ototoxicity, Unspecified Adult Solid Tumor
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients…
- Trial name
- NCT00477607
- Testing
- alpha-lipoic acid, Audiology, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- US Department of Veterans Affairs
Ototoxicity, Drug-Induced, Ototoxicity, Radiation-Induced
Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood
This study is aimed at people treated for cancer before the age of 25, who have been followed for at least 5 years, and who are now aged between 18 and 50. It is a prospective, multicenter, non-randomized study.
- Conditions
- Ototoxicity, Drug-Induced, Ototoxicity, Radiation-Induced, Pediatric Cancer
- Trial name
- RISP-OTOTOX (NCT06957132)
- Testing
- Audiogram
- Where
- 3 sites in France
- Volunteers
- 500 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Hearing Loss, Extreme
Protective Effect of N-acetylcysteine Against From Ototoxicity
Peritonitis is currently one of the leading complications of continuous ambulatory peritoneal dialysis (CAPD). Aminoglycosides and vancomycin are used in the treatment of CAPD peritonitis despite their potential risk for…
- Trial name
- NCT01271088
- Testing
- N-acetylcysteine
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- TC Erciyes University
Liver Cancer, Ototoxicity
Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- SIOPEL6 (NCT00652132)
- Testing
- cisplatin, sodium thiosulfate
- Where
- 16 sites in United Kingdom
- Volunteers
- 116 people
- Sponsor
- University of Birmingham
Childhood Cancer, Hearing Loss
Screening for Hearing Loss After Childhood Cancer
The HEAR-study pilots and evaluates a national, low-threshold screening program to detect hearing problems in Swiss adult childhood cancer survivors.
- Trial name
- HEAR (NCT06036407)
- Testing
- Hearing test
- Where
- Switzerland
- Volunteers
- 476 people
- Sponsor
- University of Bern
Ototoxic Hearing Loss, Ototoxicity, Drug-Induced
Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer
The goal of this observational study is to learn about the occurrence of and to identify suitable strategies for screening and monitoring of inner ear damage in patients receiving cisplatin chemoradiotherapy for head and neck…
- Conditions
- Ototoxic Hearing Loss, Ototoxicity, Drug-Induced, Cisplatin-induced Hearing Loss, Cisplatin Ototoxicity
- Trial name
- NCT06929468
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Simon Jäger
Mucositis, Nephrotoxicity
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients.
- Conditions
- Mucositis, Nephrotoxicity, Ototoxicity
- Trial name
- NCT03480971
- Testing
- Tempol
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Matrix Biomed, Inc.
Cisplatin, Ototoxicity
Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin.
In this study we will aim to determine if cisplatin ototoxicity can be prevented by intratympanic administration of corticosteroids.
- Conditions
- Cisplatin, Ototoxicity, Intratympanic Steroids
- Trial name
- NCT01285674
- Testing
- Intra-tympanic Cisplatinum
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Ziv Hospital
Malignant Neoplasm, Ototoxicity
Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin
This randomized pilot clinical trial studies dexamethasone in preventing hearing loss in patients receiving cisplatin. Injecting a steroid, such as dexamethasone, behind the eardrum before chemotherapy may help protect against…
- Trial name
- NCT02382068
- Testing
- Dexamethasone, Cisplatin
- Sponsor
- Aaron Moberly
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Head and Neck Cancer, Ototoxicity
Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Conditions
- Head and Neck Cancer, Ototoxicity, Radiation Toxicity
- Trial name
- NCT01216800
- Testing
- adjuvant therapy, assessment of therapy complications, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Cisplatin-induced Ototoxicity, Sensorineural Hearing Loss
Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial
The purpose of this study is to evaluate the efficacy of N-acetylcysteine (NAC) in preventing cisplatin-induced ototoxicity in patients receiving cisplatin-based chemotherapy.
- Conditions
- Cisplatin-induced Ototoxicity, Sensorineural Hearing Loss, Ototoxicity, Ototoxicity, Drug-Induced
- Trial name
- NCT07364747
- Testing
- Acetyl cysteine, Normal Saline
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Siriraj Hospital
Head Cancer, Neck Cancer
Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study
The aim of the AURACCO study is to evaluate the association between the onset of tinnitus and hearing loss in patients with locally advanced head and neck cancer treated by concomitant chemoradiotherapy or exclusive radiotherapy
- Trial name
- AURACCO (NCT05946577)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Cancer, Head and Neck Cancer
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Chemotherapy treatment with platinum based agents is well noted to cause ototoxicity. It is the objective of this study to determine the safety and efficacy of SPI-1005 at three dose levels when delivered orally twice daily for 3…
- Conditions
- Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity
- Trial name
- NCT01451853
- Testing
- SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose
- Where
- United States
- Sponsor
- Sound Pharmaceuticals, Incorporated